Our Company
About Us
About Xanamem
®
(emestedastat)
Our Team
Recent Annual Reports
Our Strategic Priorities
Corporate Governance
Xanamem
®
(emestedastat)
The Cortisol Hypothesis
Mechanism of Action
Publications
Clinical Trials
Clinical Development Pipeline
Cognitive Impairment in early Alzheimer’s Disease
Cognitive Impairment in MDD
Anxiety, sleep & behavioral problems in Fragile X Syndrome
Patient Portal
Participate in clinical trials
The XanaMIA Phase 2b/3 Alzheimer’s Trial
Publications
Investor Centre
Share Price
ASX Announcements
Press Releases
Corporate Presentations
Analyst Reports
Financial Results Centre
Annual General Meeting
General Meeting
Financial Calendar
Target Market Determination
Right to Receive Documents
Frequently Asked Questions
Investor Contacts
News
Contact Us
Share Price
Summary
Share Price
ASX Announcements
Press Releases
Corporate Presentations
Latest results
2024 Full Year Financial results
View Results Centre
2024 Annual General Meeting
Actinogen’s next Annual General Meeting
Date: 14 November 2024
Read more
Back
to top
